Maswood S, Andrade M, Caldarola-Pastuszka M, Uphouse L
Department of Biology, Texas Woman's University, Denton 76204, USA.
Neuropharmacology. 1996 Apr;35(4):497-501. doi: 10.1016/0028-3908(95)00195-6.
Sexually receptive proestrous rats were infused bilaterally into the ventromedial nucleus of the hypothalamus (VMN) with 200 ng of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), 1000 or 2000 ng of 5-methoxy-3-(di-n-propylamino) chroman (5-MEO-DPAC), or 1000 or 2000 ng of serotonin (5-HT) plus or minus the 5-HT2A/2C agonist, (2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI). DOI protected against the lordosis-inhibiting effects of 5-HT and each of the 5-HT1A agonists. These results substantiate a prior report that 2000 ng DOI could protect against the lordosis-inhibiting action of 200 ng 8-OH-DPAT and demonstrate that such protection is not unique to a single 5-HT1A agonist. Consequently, these results strengthen evidence that functionally significant interactions occur among 5-HT receptors within the VMN.
对处于发情前期且具有性接受能力的大鼠，双侧下丘脑腹内侧核（VMN）分别注射200纳克的8-羟基-2-（二正丙基氨基）四氢萘（8-OH-DPAT）、1000或2000纳克的5-甲氧基-3-（二正丙基氨基）色满（5-MEO-DPAC），或1000或2000纳克的5-羟色胺（5-HT），同时添加或不添加5-HT2A/2C激动剂（2,5-二甲氧基-4-碘苯基）-2-氨基丙烷盐酸盐（DOI）。DOI可对抗5-HT以及每种5-HT1A激动剂对脊柱前凸的抑制作用。这些结果证实了之前的一份报告，即2000纳克DOI可对抗200纳克8-OH-DPAT对脊柱前凸的抑制作用，并表明这种保护作用并非单一5-HT1A激动剂所特有。因此，这些结果进一步证明了VMN内5-HT受体之间存在功能上显著的相互作用。
